Ionis (IONS) Rule 144 Notice — 28,000 Shares via UBS on NASDAQ
Rhea-AI Filing Summary
Notice of proposed sale under Rule 144: The filing reports the proposed sale of 28,000 common shares, acquired the same day by exercise of stock options and paid in cash. The broker named is UBS Financial Services, Inc. (11 Madison Avenue, New York). The aggregate market value of the shares is listed as $1,680,000.00, with 159,391,229 shares outstanding and an approximate sale date of 09/03/2024 on NASDAQ. The filer reports no securities sold in the past three months and includes the standard signature representation re: material nonpublic information and Rule 10b5-1 plan language.
Positive
- Full disclosure of transaction mechanics: acquisition date, nature (option exercise), payment method, broker, and planned sale date are provided
- No reported sales in prior three months, suggesting this may be a one-off disposition rather than ongoing insider selling
Negative
- Issuer and filer identity fields are incomplete in the form content, limiting context about the specific insider or corporate role
- No detail on whether a Rule 10b5-1 plan applies beyond the generic representation, so the filing does not clarify pre-arranged trading instructions
Insights
TL;DR: Insider exercised options and intends to sell 28,000 shares via UBS on NASDAQ, representing a routine Rule 144 notice.
The filing documents a same-day option exercise and proposed sale of 28,000 common shares with an aggregate market value of $1.68M. The transaction is routed through a major broker and scheduled for 09/03/2024. No prior sales in the past three months are reported, which may indicate this is an isolated disposition rather than part of a recurring selling pattern. The filing includes the required representation that the seller is not aware of undisclosed material adverse information.
TL;DR: This is a standard Rule 144 notice documenting an option exercise and planned market sale; disclosures appear routine.
The notice provides necessary mechanics: acquisition date, nature of acquisition (stock option exercise), payment in cash, broker details, and outstanding share count. The absence of reported sales in the prior three months and the inclusion of the signature representation align with typical compliance practices. No governance concerns or material adverse events are disclosed in this filing.